1-[12-(1-Carbamoyl-cyclopropyl)-dodecyl]-cyclopropanecarboxylic acid | 1365571-83-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-[12-(1-Carbamoyl-cyclopropyl)-dodecyl]-cyclopropanecarboxylic acid
• 英文别名: 1-[12-(1-carbamoylcyclopropyl)dodecyl]cyclopropane-1-carboxylic acid
• CAS: 1365571-83-0
• 化学式: C₂₀H₃₅NO₃
• 分子量: 337.503
• InChiKey: MPEATPDVWLQLTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,15-dicyclopropyl-hexadecanedioic acid 在 N,N-二甲基甲酰胺 氯化亚砜 、 草酰氯 、 氨 、 水 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 27.5h， 生成 1-[12-(1-Carbamoyl-cyclopropyl)-dodecyl]-cyclopropanecarboxylic acid
  参考文献：
  名称：

  METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA

  摘要：

  该发明涉及一种新型化合物的公式I：以及其立体异构体和/或药用盐，用于治疗糖尿病和与糖尿病相关的血脂异常。

  公开号：

  US20120071528A1

文献信息

• Methods and compositions for treatment of diabetes and dyslipidemia
  申请人：Khanna Ish

  公开号：US08623897B2

  公开（公告）日：2014-01-07

  The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

  本发明涉及一种新的化合物I，以及它的立体异构体和/或药学上可接受的盐，用于治疗糖尿病和与糖尿病相关的血脂异常。
• Substituted cycloalkanes for managing nephrogenic diabetes insipidus
  申请人：NephroDI Therapeutics, Inc.

  公开号：US11179354B2

  公开（公告）日：2021-11-23

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

  在某些实施方案中，本公开涉及治疗或预防肾源性糖尿病的方法，包括向有需要的受试者施用有效量的如本文所述的式(I)化合物或其衍生物。在某些实施方案中，受试者已被诊断为肾源性糖尿病。
• Managing Nephrogenic Diabetes Insipidus
  申请人：Emory University

  公开号：US20200383940A1

  公开（公告）日：2020-12-10

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
• SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS
  申请人：NephroDI Therapeutics, Inc.

  公开号：US20220031639A1

  公开（公告）日：2022-02-03

  In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
• US8623897B2
  申请人：——

  公开号：US8623897B2

  公开（公告）日：2014-01-07